<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04485884</url>
  </required_header>
  <id_info>
    <org_study_id>IN_BTK_101</org_study_id>
    <nct_id>NCT04485884</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of IN-C005 in Healthy Male Subjects</brief_title>
  <official_title>An Open-label, Randomized, Single and Multiple Dosing Phase I Clinical Trial to Evaluate Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of IN-C005 After Oral Administration in Healthy Korean and Caucasian Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate pharmacokinetics/pharmacodynamics and
      safety/tolerability of IN-C005 after oral administration in healthy Korean and Caucasian male
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      [Pharmacokinetic Assessments]: Plasma concentrations of IN-C005 and its metabolite will be
      measured

        1. Single Dosing Group (Korean Subjects)

             -  Primary endpoints: Cmax and AUClast of IN-C005

             -  Secondary endpoints: AUClast, Cmax, AUCinf, Tmax, t½, CL/F, and Vd/F of M1; AUCinf,
                Tmax, t½, CL/F, and Vd/F of IN-C005

        2. Multiple Dosing Group (Caucasian Subjects)

             -  Primary endpoints: Cmax, AUClast, Cmax,ss, and AUCτ,ss of IN-C005

             -  Secondary endpoints: For M1, AUClast, Cmax, Cmax,ss, AUCinf, AUCτ,ss, Tmax,
                Tmax,ss, t½, CL/F, and Vd/F; for IN-C005, AUCinf, Tmax, Tmax,ss, Cmin,ss, t½, CL/F,
                Vd/F, Cav,ss, CLss/F, Vss/F, PTF (peak to trough fluctuation), and R (accumulation
                ratio)

      [Pharmacodynamic Assessments]:

        1. Single Dosing Group (Korean Subjects)

             -  Intragastric pH

                  -  Percent (%) duration of pH ≥4 in 24 hrs

                  -  Mean pH

                  -  Median pH

                  -  Change in pH from baseline to post-dose (Δduration %, Δmean pH, Δmedian pH,
                     etc.)

             -  Serum gastrin level

                  -  AUEGlast

                  -  Gmax

                  -  Change in gastrin level from baseline to study treatment (1d, 8d, and
                     15d)(ΔAUEGlast, ΔGmax, etc.)

        2. Multiple Dosing Group (Caucasian Subjects)

             -  Intragastric pH

                  -  Percent (%) duration of pH ≥4 in 24 hrs

                  -  Mean pH

                  -  Median pH

                  -  Change in pH from baseline to post-single dose and post-multiple doses
                     (Δduration %, Δmean pH, Δmedian pH, etc.)

             -  Serum gastrin level

                  -  AUEGlast

                  -  Gmax

                  -  Change in gastrin level from baseline to 1d and 7d (ΔAUEGlast, ΔGmax, etc.)

      [Safety Assessments] &lt;Single Dosing Group (Korean Subjects) and Multiple Dosing Group
      (Caucasian Subjects)&gt;

        1. AEs will be monitored with observable/objective symptoms, etc.

        2. Physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory
           tests
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Evaluation [Single Dosing Group (Korean Subjects), Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Cmax of IN-C005</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Evaluation [Single Dosing Group (Korean Subjects), Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>AUClast of IN-C005</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Cmax,ss of IN-C005</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>AUCtau,ss of IN-C005</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Single Dosing Group (Korean Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>AUClast of M1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Single Dosing Group (Korean Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Cmax of M1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Single Dosing Group (Korean Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>AUCinf of IN-C005 and M1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Single Dosing Group (Korean Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Tmax of IN-C005 and M1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Single Dosing Group (Korean Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>t½ of IN-C005 and M1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Single Dosing Group (Korean Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>CL/F of IN-C005 and M1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Single Dosing Group (Korean Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Vd/F of IN-C005 and M1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>AUClast of M1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Cmax of M1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Cmax,ss of M1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>AUCinf of IN-C005 and M1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>AUCtau,ss of M1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Tmax of IN-C005 and M1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Tmax,ss of IN-C005 and M1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>t½ of IN-C005 and M1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>CL/F of IN-C005 and M1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Vd/F of IN-C005 and M1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Cmin,ss of IN-C005</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Cav,ss of IN-C005</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>CLss/F of IN-C005</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Vss/F of IN-C005</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>PTF (peak to trough fluctuation) of IN-C005</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>R (accumulation ratio) of IN-C005</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Evaluation [Single Dosing Group (Korean Subjects)]</measure>
    <time_frame>Pre-dose(0h) up to 24 hours after IP administration in each period</time_frame>
    <description>Percent (%) duration of pH ≥ 4 in 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Evaluation [Single Dosing Group (Korean Subjects)]</measure>
    <time_frame>Pre-dose(0h) up to 24 hours after IP administration in each period</time_frame>
    <description>Mean pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Evaluation [Single Dosing Group (Korean Subjects)]</measure>
    <time_frame>Pre-dose(0h) up to 24 hours after IP administration in each period</time_frame>
    <description>Median pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Evaluation [Single Dosing Group (Korean Subjects)]</measure>
    <time_frame>Pre-dose(0h) up to 24 hours after IP administration in each period</time_frame>
    <description>Change in pH from baseline to post-dose of Δduration %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Evaluation [Single Dosing Group (Korean Subjects)]</measure>
    <time_frame>Pre-dose(0h) up to 24 hours after IP administration in each period</time_frame>
    <description>Change in pH from baseline to post-dose of Δmean pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Evaluation [Single Dosing Group (Korean Subjects)]</measure>
    <time_frame>Pre-dose(0h) up to 24 hours after IP administration in each period</time_frame>
    <description>Change in pH from baseline to post-dose of Δmedian pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Evaluation [Single Dosing Group (Korean Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>AUEGlast(Area under the concentration-time curve of serum gastrin from time zero to the last point of quantifiable concentration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Evaluation [Single Dosing Group (Korean Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Gmax (Maximum plasma concentration of gastrin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Evaluation [Single Dosing Group (Korean Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Change in gastrin level from baseline to 1d and 7d of ΔAUEGlast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Evaluation [Single Dosing Group (Korean Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Change in gastrin level from baseline to 1d and 7d of ΔGmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Pre-dose(0h) up to 24 hours after IP administration in each period</time_frame>
    <description>Percent (%) duration of pH ≥ 4 in 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Pre-dose(0h) up to 24 hours after IP administration in each period</time_frame>
    <description>Mean pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Pre-dose(0h) up to 24 hours after IP administration in each period</time_frame>
    <description>Median pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Pre-dose(0h) up to 24 hours after IP administration in each period</time_frame>
    <description>Change in pH from baseline to post-single dose and post-multiple dose (Δduration %, Δmean pH, Δmedian pH, etc)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Evaluation [Multiple Dosing Group (Caucasian Subjects)]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>AUEGlast(Area under the concentration-time curve of serum gastrin from time zero to the last point of quantifiable concentration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Evaluation [Multiple Dosing Group (Caucasian Subjects]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Gmax (Maximum plasma concentration of gastrin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Evaluation [Multiple Dosing Group (Caucasian Subjects]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Change in gastrin level from baseline to 1d and 7d of ΔAUEGlast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Evaluation [Multiple Dosing Group (Caucasian Subjects]</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Change in gastrin level from baseline to 1d and 7d of ΔGmax</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IN-C005 dose A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IN-C005 dose B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IN-C005 dose C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IN-C005 dose D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IN-C005 dose E</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IN-C005 dose F</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IN-C005 dose A</intervention_name>
    <description>One time dose of IN-C005 dose A taken orally.</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>IN-C005</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IN-C005 dose B</intervention_name>
    <description>One time dose of IN-C005 dose B taken orally.</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>IN-C005</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IN-C005 dose C</intervention_name>
    <description>One time dose of IN-C005 dose C taken orally.</description>
    <arm_group_label>Group C</arm_group_label>
    <other_name>IN-C005</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IN-C005 dose D</intervention_name>
    <description>Oral administration of IN-C005 dose D once daily for 7 days.</description>
    <arm_group_label>Group D</arm_group_label>
    <other_name>IN-C005</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IN-C005 dose E</intervention_name>
    <description>Oral administration of IN-C005 dose E once daily for 7 days.</description>
    <arm_group_label>Group E</arm_group_label>
    <other_name>IN-C005</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IN-C005 dose F</intervention_name>
    <description>Oral administration of IN-C005 dose F once daily for 7 days.</description>
    <arm_group_label>Group F</arm_group_label>
    <other_name>IN-C005</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  [For single dosing group only] Healthy Korean male aged 19 to 50 years (inclusive) at
             the time of signing the informed consent form (ICF)

          -  [For multiple dosing group only] Healthy Caucasian male aged 19 to 50 years
             (inclusive) at the time of signing the ICF (Caucasian subject is defined as a European
             who was born in Europe, has the duration of residence outside of Europe less than 10
             years, and both of whose parents and grandparents are European-born).

          -  Body mass index (BMI) of ≥ 18.0 and ≤ 28.0 kg/m2 with a body weight ≥ 55.0 kg at
             screening. (BMI (kg/m2) = weight (kg) / {height (m)}2)

          -  Subjects with negative result in serum Helicobacter pylori antibody test.

          -  Voluntary participation in the study after being fully informed of and understanding
             the study completely, and provides his written informed consent prior to screening
             procedure

          -  Subjects who are eligible for this study in the opinion of the investigator based on
             the results of physical examination, clinical laboratory tests, interview, etc.

        Exclusion Criteria:

          -  History or current evidence of clinically significant disorder of hepatic, renal,
             nervous, respiratory, endocrine, hemato-oncologic, cardiovascular, urinary, and/or
             psychiatric system.

          -  History or current evidence of gastrointestinal disease that may affect the safety and
             PD assessment for study treatment (e.g., gastrointestinal ulcer, gastritis, gastric
             cramp, gastroesophageal reflux disease, and Crohn's disease) or a history of
             gastrointestinal surgery (except for simple appendectomy or herniotomy).

          -  History or current evidence of clinically significant hypersensitivity to drugs
             containing IN-C005 or any ingredient of proton pump inhibitors and other drugs (such
             as aspirin and antibiotics).

          -  Subjects with positive result on serology tests (for hepatitis B, human
             immunodeficiency virus [HIV], and hepatitis C).

          -  Subjects with blood level of total bilirubin, AST (GOT), or ALT (GPT) &gt; 1.5 X upper
             limit of normal range(ULN) at procedures performed during the screening period
             including those performed additionally.

          -  Subjects with eGFR &lt; 60 ml/min/1.73m2 during the screening period including those
             performed additionally.

          -  Systolic blood pressure (SBP) of &lt; 90 mmHg or &gt; 140 mmHg, diastolic blood pressure
             (DBP) of &lt; 50 mmHg or &gt; 95 mmHg, or pulse rate of &lt; 45 beats/min or &gt; 100 beats/min on
             vital signs as measured in sitting position after taking a rest for at least 5 minutes
             at screening.

          -  Subjects with anatomical disorder that precludes insertion and maintenance of
             intragastric pH meter catheter or is expected to be intolerable to insertion of
             intragastric pH meter catheter.

          -  History of drug abuse or positive response to drug abuse on urine drug screening test.

          -  Subjects who received any prescription drug or herbal medication within 2 weeks of or
             any over-the-counter (OTC) drug, dietary supplements, or vitamins within 1 week of
             scheduled first dose or subjects who are expected to receive such medication during
             the study. (Note: a subject may participate in the study at the discretion of the
             investigator, provided that the subject meets all the other criteria).

          -  Subjects who participated in any other clinical study or bioequivalence study and
             received investigational product within 6 months prior to the scheduled first dose.

          -  Subjects who have donated whole blood within 2 months prior to the scheduled first
             dose, or have donated blood components or received transfusion within a month prior to
             the scheduled first dose.

          -  Excessive caffeine intake (&gt; 5 units/day), continued use of alcohol (&gt; 21 units/week,
             1 unit = 10 g of pure alcohol), or inability to stop drinking while hospitalized.

          -  Positive result for cotinine on urine drug screening test or inability to quit smoking
             throughout the study.

          -  Subjects who have taken grapefruit-containing foods during the period from 24 hours
             (hrs) before hospitalization to discharge, or are unable to avoid
             grapefruit-containing foods during this period.

          -  Subjects who are unable to avoid caffeine-containing foods (e.g., coffee, tea [red
             tea, green tee, etc.], soda, coffee milk, and nutritive tonic drink) during the period
             from 24 hrs before hospitalization to discharge.

          -  Subjects who are unable to use medically acceptable contraceptive methods throughout
             the study.

             ► Medically acceptable contraceptive methods include:

             ① Use of intrauterine device with a proven birth control failure rate by the spouse
             (or partner);

             ② Simultaneous use of (male or female) barrier method and spermicide; and

             ③ Surgical sterilization of the subject or his partner (e.g., vasectomy,
             salpingectomy, tubal ligation, or hysterectomy).

          -  Subjects who are determined ineligible for study participation by the investigator for
             other reasons such as clinical laboratory abnormalities.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jin Jang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital, Clinical Trial Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Youngshin Keum, Pharm.D</last_name>
    <phone>+82-2-6477-0204</phone>
    <email>ys.keum@inno-n.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seokuee Kim, MD, PhD</last_name>
    <phone>+82-2-6477-0207</phone>
    <email>seokuee.kim@inno-n.com</email>
  </overall_contact_backup>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

